Trials / Completed
CompletedNCT03964649
Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics
Comparative Analysis of Outcomes Among Rheumatoid Arthritis Patients Treated With Xeljanz Versus Biologic DMARDs Using a United States Healthcare Claims Database
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,308 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
To compare rheumatoid arthritis (RA) patient characteristics, adherence, and costs between patients treated with tofacitinib (IR, XR and combined groups) to patients treated with each of the bDMARDs.
Conditions
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2020-04-06
- Completion
- 2020-04-06
- First posted
- 2019-05-28
- Last updated
- 2021-06-02
- Results posted
- 2021-04-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03964649. Inclusion in this directory is not an endorsement.